The Pathogenesis of Vascular Calcification in the Chronic Kidney Disease Mineral Bone Disorder: The Links Between Bone and the Vasculature

Seminars in Nephrology

Volumn 29, Issue 2, 2009, Pages 156-165

  Hruska, Keith A ^a   Mathew, Suresh ^a   Lund, Richard J ^b   Memon, Imran ^a   Saab, Georges ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular disease; fetuin A; matrix Gla protein; phosphorus; Vascular calcifications; vascular smooth muscle; vitamin D

Indexed keywords

BONE MORPHOGENETIC PROTEIN; FETUIN A; FIBROBLAST GROWTH FACTOR 23; OSTEOCALCIN; OSTEOGENIC PROTEIN 1; OSTEOPONTIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; TRANSCRIPTION FACTOR RUNX2; VITAMIN D; WNT PROTEIN;

ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DEVELOPMENT; BONE METABOLISM; BONE MINERALIZATION; CELL DIFFERENTIATION; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; HUMAN; MESENCHYMAL STEM CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR SMOOTH MUSCLE;

BLOOD VESSELS; BONE DISEASES, METABOLIC; CALCINOSIS; CALCIUM; HUMANS; KIDNEY FAILURE, CHRONIC; VASCULAR DISEASES;

EID: 64049095508     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2009.01.008     Document Type: Article

References (70)

1. Ejerblad S., Ericsson J.L.E., and Eriksson I. Arterial lesions of the radial artery in uraemic patients. Acta Chir Scand 145 (1979) 415-428
2. Elliott R.J., and McGrath L.T. Calcification of the human aorta during aging. Calcif Tissue Int 54 (1994) 268-273
3. Edmonds M.E. Medial arterial calcification and diabetes mellitus. Z Kardiol 89 (2000) II/101-4
4. Blacher J., Safar M.E., Guerin A.P., Pannier B., Marchais S.J., and London G.M. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 63 (2003) 1852-1860
5. Raggi P., Boulay A., Chasan-Taber S., Amin N., Dillon M., Burke S.K., et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?. J Am Coll Cardiol 39 (2002) 695-701
6. Goodman W.G., Goldin J., Kuizon B.D., Yoon C., Gales B., Sider D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 (2000) 1478-1483
7. Cheng H., Jiang W., Phillips F.M., Haydon R.C., Peng Y., Zhou L., et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg 85 (2003) 1544-1552
8. Kato M., Patel M.S., Levasseur R., Lobov I., Chang B.H.J., Glass II D.A., et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157 (2002) 303-314
9. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89 (1997) 755-764
10. Nakashima K., Zhou X., Kunkel G., Zhang Z., Deng J.M., Behringer R.R., et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108 (2002) 17-29
11. Satokata I., and Mass R. Msx1 deficient mice exhibit cleft palate and abnormalities of craniofacial and tooth development. Nat Genet 6 (1994) 348-356
12. Satokata I., Ma L., Ohshima H., Bei M., Woo I., Nishizawa K., et al. Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat Genet 24 (2004) 391-395
13. Towler D.A., Bidder M., Latifi T., Coleman T., and Semenkovich C.F. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem 273 (1998) 30427-30434
14. Tyson K.L., Reynolds J.L., McNair R., Zhang Q., Weissberg P.L., and Shanahan C.M. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 23 (2003) 489-494
15. Moe S.M., O'Neill K.D., Duan D., Ahmed S., Chen N.X., Leapman S.B., et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61 (2002) 638-647
16. Hedin U., Roy J., Tran P.K., Lundmark K., and Rahman A. Control of smooth muscle cell proliferation-the role of the basement membrane. Thromb Haemost 82 Suppl (1999) 23-26
17. Worth N.F., Rolfe B.E., Song J., and Campbell R. Vascular smooth muscle cell phenotypic modulation in culture is associated with reorganization of contractile and cytoskeletal proteins. Cell Motil Cytoskeleton 49 (2001) 130-145
18. Thyberg J. Differentiated properties and proliferation of arterial smooth muscle cells in culture. Int Rev Cytol 169 (1996) 183-265
19. Brennan M.J., Millis A.J., and Fritz K.E. Fibronectin inhibits morphological changes in vascular smooth muscle cells. J Cell Physiol 112 (1982) 284-290
20. Barone L.M., Owen T.A., and Tassinari M.S. Developmental expression and hormonal regulation of the rat matrix gla protein (MGP) gene in chondrogenesis and osteogenesis. J Cell Biochem 46 (1991) 351-365
21. Boström K., Watson K.E., Horn S., Worthman C., Herman I.M., and Demer L.L. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 91 (1993) 1800-1809
22. Shioi A., Nishizawa Y., Jono S., Koyama H., Hosoi M., and Morii H. b-Glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 15 (1995) 2003-2009
23. Mathew S., Tustison K.S., Sugatani T., Chaudhary L.R., Rifas L., and Hruska K.A. The mechanism of phosphorus as a cardiovascular risk factor in chronic kidney disease. J Am Soc Nephrol 19 (2008) 1092-1105
24. Jono S., McKee M.D., Murry C.E., Shioi A., Nishizawa Y., Mori K., et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87 (2000) e10-e17
25. Chen N.X., O'Neill K.D., Duan D., and Moe S.M. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 62 (2002) 1724-1731
26. Roy M.E., and Nishimoto S.K. Matrix Gla protein binding to hydroxyapatite is dependent on the ionic environment: calcium enhances binding affinity but phosphate and magnesium decrease affinity. Bone 31 (2002) 296-302
27. Yagami K., Suh J.Y., Enomoto-Iwamoto M., Koyama E., Abrams W.R., Shapiro I.M., et al. Matrix GLA protein is a developmental regulator of chondrocyte mineralization and, when constitutively expressed, blocks endochondral and intramembranous ossification in the limb. J Cell Biol 147 (1999) 1097-1108
28. Luo G., Ducy P., McKee M.D., Pinero G.J., Loyer E., Behringer R.R., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386 (1997) 78-81
29. Steitz S.A., Speer M.Y., Curinga G., Yang H.-Y., Haynes P., Aebersold R., et al. Smooth muscle cell phenotypic transition associated with calcification. Circ Res 89 (2001) 1147-1154
30. Bostrom K., Tsao D., Shen S., Wang Y., and Demer L.L. Matrix GLA protein modulates differentiation induced by bone morphogenetic protein-2 in C3H10T1/2 cells. J Biol Chem 276 (2001) 14044-14052
31. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpleyl J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 (1998) 1260-1268
32. Nakamura M., Udagawa N., Matsuura S., Mogi M., Nakamura H., Horiuchi H., et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144 (2003) 5441-5449
33. Min H., Morony S., Sarosi I., Dunstan C.R., Capparelli C., Scully S., et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192 (2000) 463-474
34. Kaden J.J., Bickelhaupt S., Grobholz R., Haase K.K., Sarikoc A., Kilic R., et al. Receptor activator of nuclear factor kB ligand and osteoprotegerin regulate aortic valve calcification*1. J Mol Cell Cardiol 36 (2004) 57-66
35. Price P.A., Faus S.A., and Williamson M.K. Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 20 (2000) 317-327
36. Price P.A., Faus S.A., and Williamson M.K. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21 (2001) 817-824
37. Price P.A., June H.H., Buckley J.R., and Williamson M.K. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 21 (2001) 1610-1616
38. 3 stimulates bone formation and increases the number of osteoblast precursor cells in bone marrow. Endocrinology 138 (1997) 4629-4635
39. Price P.A., June H.H., Buckley J.R., and Williamson M.K. SB 242784, a selective inhibitor of the osteoclastic V-H+-ATPase, inhibits arterial calcification in the rat. Circ Res 91 (2002) 547-552
40. Kitazawa S., Kajimoto K., Kondo T., and Kitazawa R. Vitamin D3 supports osteoclastogenesis via functional vitamin d response element of human RANKL gene promoter. J Cell Biochem 89 (2003) 771-777
41. Mathew S, Strebeck F, Hruska KA. The protective actions of vitamin D analogs in the vascular calcification of chronic kidney disease (CKD). J Am Soc Nephrol. In press.
42. Elzanowski A., Barker W.C., Hunt L.T., and Seibel-Ross E. Cystatin domains in alpha-2-HS glycoprotein and fetuin. FEBS Lett 227 (1988) 167-170
43. Schinke T., Amendt C., Trindl A., Poschke O., Muller-Esterl W., and Jahnen-Dechent W. The serum protein a2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. J Biol Chem 271 (1996) 20789-20796
44. Demetriou M., Binkert C., Sukhu B., Tenenbaum H.D., and Dennis J.W. Fetuin/alpha2-HS glycoprotein is transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem 271 (1996) 12755-12761
45. Binkert C., Demetriou M., Sukhu B., Szweras M., Tennenbaum H.C., and Dennis J.W. Regulation of osteogenesis by fetuin. J Biol Chem 274 (1999) 28514-28520
46. Schafer C., Heiss A., Schwarz A., Westenfeld R., Ketteler M., Floege J., et al. The serum protein {alpha}2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112 (2003) 357-366
47. Ketteler M., Bongartz P., Westenfeld R., Wildberger J.E., Mahnken A.H., Bohm R., et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361 (2003) 827-833
48. Lebreton J.P., Joisel F., Raoult J.P., Lannuzel B., Rogez J.P., and Humbert G. Serum concentration of human alpha 2-HS glycoprotein during the inflammatory process: evidence that alpha 2-HS glycoprotein is a negative acute-phase reactant. J Clin Invest 64 (1979) 1118-1129
49. Simon M., Maresh J.G., Harris S.E., Hernandez J.D., Arar M., Olson M.S., et al. Expression of bone morphogenetic protein-7 mRNA in normal and ischemic adult rat kidney. Am J Physiol 276 (1999) F382-F389
50. Wang S., Chen Q., Simon T.C., Strebeck F., Chaudhary L., Morrissey J., et al. Bone morphogenetic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 63 (2003) 2037-2049
51. Wang S., and Hirschberg R. Loss of renal tubular BMP7 during the evolution of experimental diabetic nephropathy. J Am Soc Nephrol 11 (2000) 655A
52. Davies M.R., Lund R.J., Mathew S., and Hruska K.A. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 16 (2005) 917-928
53. Gonzalez E.A., Lund R.J., Martin K.J., McCartney J.E., Tondravi M.M., Sampath T.K., et al. Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7. Kidney Int 61 (2002) 1322-1331
54. Davies M.R., Lund R.J., and Hruska K.A. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 14 (2003) 1559-1567
55. Dorai H., Vukicevic S., and Sampath T.K. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 184 (2000) 37-45
56. Kokubo T, Uchida H, Chasnoff SE, Matthew S, Hruska KA, Choi ET. Chronic kidney disease (CKD) accelerates development of neointimal hyperplasia in a mouse arteriovenous fistula model. J Am Soc Nephrol. In press.
57. White K.E., Evans W.E., O'Riordan J.L.H., Speer M.C., Econs M.J., Lorenz-Depiereux B., et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26 (2000) 345-348
58. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98 (2001) 6500-6505
59. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113 (2004) 561-568
60. Larsson T., Nisbeth U., Ljunggren O., Juppner H., and Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64 (2003) 2272-2279
61. Weber T.J., Liu S., Indridason O.S., and Quarles L.D. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18 (2003) 1227-1234
62. Razzaque M.S., Sitara D., Taguchi T., St-Arnaud R., and Lanske B. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 20 (2006) 720-722
63. Gutierrez O.M., Mannstadt M., Isakova T., Rauh-Hain J.A., Tamez H., Shah A., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359 (2008) 584-592
64. Wang L., Banu J., Mcmahan C.A., and Kalu D.N. Male rodent model of age-related bone loss in men. Bone 29 (2001) 141-148
65. Clarke B.L., Ebeling P.R., Jones J.D., Wahner H.W., O'Fallon W.M., Riggs B.L., et al. Changes in quantitative bone histomorphometry in aging healthy men. J Clin Endocrinol Metab 81 (1996) 2264-2270
66. Suzuki K., Miyakoshi N., Tsuchida T., Kasukawa Y., Sato K., and Itoi E. Effects of combined treatment of insulin and human parathyroid hormone(1-34) on cancellous bone mass and structure in streptozotocin-induced diabetic rats. Bone 33 (2003) 108-114
67. Krakauer J.C., McKenna M.J., Buderer N.F., Rao D.S., Whitehouse F.W., and Parfitt A.M. Bone loss and bone turnover in diabetes. Diabetes 44 (1995) 775-782
68. Shao J.S., Cheng S.L., Charlton-Kachigian N., Loewy A.P., and Towler D.A. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 278 (2003) 50195-50202
69. Lund R.J., Davies M.R., Brown A.J., and Hruska K.A. Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol 15 (2004) 359-369
70. Hruska K.A., Saab G., Chaudhary L.R., Quinn C.O., Lund R.J., and Surendran K. Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. Semin Nephrol 24 (2004) 25-38